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INTRODUCTION
Epidemiological studies by the Japanese Circulation Society
have shown that approximately 800,000 patients have atrial fibrilla-
tion (AF). It has also been reported that the number of such patients
will surpass one million in 2030 (1). Cardiogenic cerebral embo-
lism with AF greatly decreases patients’ prognosis or quality of life
compared with lacunar infarction and atherothrombotic brain in-
farction. The prognosis of cardiogenic cerebral embolism due to
AF is very poor, with an approximate 50% chance of survival one
year after diagnosis, as shown by the Hisayama Study (2). Thus, it is
very important to prevent complications in patients with AF. Thrombi
formed in the atrium are rich in fibrin (as in the case of venous
thrombi), and anticoagulant therapy is shown to be beneficial.
Warfarin (WF) therapy is recommended in the Guidelines for
Pharmacotherapy of Atrial Fibrillation (JCS Joint Working Group
2013) (3) for non-valvular AF (NVAF) patients with a risk of embo-
lism. The efficacy of WF therapy depends on the target treatment
level during the therapy ; i.e., time in therapeutic range (TTR).
Also, the international normalized ratio (INR) should be controlled
to attain target treatment levels during WF therapy. This means
that TTR markedly affects the efficacy of WF therapy ; i.e., TTR is a
quality indicator of WF control. Morgan et al. reported that TTR
and the incidence of cerebral infarction strongly correlate ; i.e.,
the incidence of cerebral infarction is low when TTR control is good
(4). When TTR is low, a lesser therapeutic effect of WF is expected,
which increases the risk of complications (5). When TTR is65%,
the therapeutic efficacy of WF cannot be achieved (6). Obtaining
good TTR control can be difficult because WF has a narrow thera-
peutic window and has many interactions with food and drugs. In a
previous study, we reported that the factors that affect TTR control
are associated with heart failure (7). Therefore, careful monitor-
ing of NVAF patients with heart failure is needed to achieve good
TTR control. However, it is difficult for physicians alone to suffi-
ciently explain the above considerations to patients ; therefore,
hospital pharmacists are required to manage TTR control.
The aim of this study was to assess TTR control of patients with
NVAF receiving WF therapy.
METHOD
1. Subjects
The inclusion criteria were as follows : [1] patients admitted to
the Cardiovascular Medicine Department of Yokosuka Kyousai
Hospital for ablation of arrhythmias between March 2011 and July
2013 and who started WF therapy ; [2] duration of WF of1 year ;
[3] Prothrombin time-INR (PT-INR) measured at least once every
12 months (7) ; and [4] NVAF patients with heart failure. The
exclusion criteria were patients with missing data and those who
had NVAF without heart failure. Guidelines for Pharmacotherapy of
Atrial Fibrillation (JCS 2013) (3) recommended a target PT-INR of
2.03.0 in NVAF patients aged70 years and a target of 1.62.6 in
those aged70 years. However, a previous report showed that a
target PT-INR of 1.62.6 in those aged70 years is effective (3).
Thus, we set the target PT-INR at 1.62.6 in the current study.PT-
INR targets in the present study are identified for the Japanese
population. In addition, all patients in the study gave their informed
consent.
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2. Study design
A retrospective cohort study was conducted using data from
medical records of the subjects. The follow-up period of sub-
jects is 1 year. We defined patients who received instruction by
hospital pharmacists in addition to instruction by physicians as
the Intervention group and who were instructed by physicians only
as the Usual care group. We compared background and laboratory
data between the two groups. Hospital pharmacists’ interventions
in Yokosuka Kyousai Hospital included the following : {1} confir-
mation of drugs or drug interactions presented at admission ; {2}
monitoring of bleeding and PT-INR ; {3} proposing to physicians
to change the dose of WF when appropriate ; {4} lifestyle precau-
tions ; {5} declaration at the visit of medical institutions ; {6} confir-
mation of interaction of WF and supplements or foods such as fer-
mented soybeans, green juice, and chlorella. Hospital pharmacists
are veteran pharmacists with a minimum of 10 years working
experience in clinical practice and instructed patients with the bro-
chure regarding the essential consideration of WF. Hospital phar-
macists randomly intervened with patients at admission. None of
the patients had complicated cases that pharmacists were able to
instruct on. All patients were able to communicate. On the other
hand, physicians’ interventions included orally instructing only the
efficacy and effect of WF at admission without using brochures on
the consideration of WF. Most physicians did not provide the pa-
tients with lifestyle guidance.
3. Clinical parameters
We examined the following parameters to elucidate any differ-
ences between the Intervention and Usual care groups. Informa-
tion regarding participant characteristics, including sex, age, weight,
body mass index (kg/m2), complications (e.g., hypertension, type 2
diabetes, stroke, transient ischemic attacks, and dyslipidemia),
smoking history, average WF dose, bleeding after WF administra-
tion, bleeding history, congestive heart failure, hypertension, age,
diabetes mellitus, stroke/transient ischemic attacks (CHADS2)
score, number of PT-INR measurements, and coefficient of vari-
ation (CV)-INR were collected via medical records.
Laboratory data, including systolic blood pressure (SBP), dia-
stolic blood pressure (DBP), aspartate aminotransferase (AST),
alanine aminotransferase (ALT), blood urea nitrogen (BUN),
serum creatinine (Scr), estimated glomerular filtration rate (eGFR),
total cholesterol (T-Cho), triacylglycerol (TG), high-density lipo-
protein cholesterol (HDL-C), low-density lipoprotein cholesterol
(LDL-C), C-reactive protein (CRP), total protein (TP), albumin
(Alb), red blood cell count (RBC), hemoglobin (Hb), hematocrit
(Hct), and brain natriuretic peptide (BNP) were collected via
medical records.
In the present study, eGFR was calculated based on the Modifica-
tion of Diet in Renal Disease (MDRD) equation as shown below.
MDRD equation based on Scr measured using the enzymatic
method was published in 1999 (8). In consideration of racial differ-
ences, The Japan Society of Nephrology announced the MDRD
formula suitable for the Japanese population in 2009.
Male : 194 × (Scr)-1.094 × (Age)-0.287
Female : 194 × (Scr)-1.094 × (Age)-0.287 × 0.739
4. Outcome measures
The primary outcome was TTR. PT-INR was measured every
12 months in the present study ; TTR was calculated using the
Rosendaal method, which calculates the ratio of the period during
PT-INR within the target treatment region from the entire meas-
urement period of PT-INR (9). In addition, the time the steady
state of WF is reached is estimated in 23 weeks from the level of
prothrombin, which has a very long half - life (i.e., 34 days). There-
fore, we calculated TTR using PT-INR after 5 days of WF admini-
stration.
Secondary outcomes were major bleeding and minorbleeding.
The present study used the bleeding criteria set by the Random-
ized Evaluation of Long-term Anticoagulant Therapy (RE-LY)
(10-11) to define bleeding after WF administration. Accordingly,
major bleeding was defined as a reduction in the Hb level of at
least 2.0 g/dL, transfusion of at least 2 units of blood, or sympto-
matic bleeding in a critical area or organ. Life - threatening bleeding
was a subcategory of major bleeding that consisted of fatal bleed-
ing, symptomatic intracranial bleeding, bleeding with a decrease in
Hb of at least 5.0 g/dL, or bleeding requiring transfusion of at
least 4 units of blood or inotropic agents or necessitating surgery.
All other bleeding was considered minor.
5. Sample size calculation
A sample size calculation was performed using Power and Sample
Size Calculation software (version 3.0, 2009, Dupont & Plummer,
Department of Biostatistics, Vanderbilt University). We planned a
study using continuous response variables from independent usual
care and intervention subjects with one instance of usual care per
intervention subject. In a previous study (12), the response within
each group was normally distributed with standard deviation
(SD) of 8.5. If the true difference between the intervention and usual
care means is 8.2, we would require 18 subjects per group to be
able to reject the null hypothesis that the population means of the
Intervention and Usual care groups are equal with probability (i.e.,
power) of 0.8. The type I error associated with this test is 0.05.
6. Statistical Analysis
Results are presented as meanSD or median (interquartile
range). We performed normality testing to compare the data
volume between Intervention and Usual care groups. When data
were normally distributed, the Student’s t - test was used to test for
significant differences between groups ; the MannWhitney U
test was used when data were not normally distributed. We used
the χ2 test or the Fisher’s exact test to compare categorical data.
The significance level was set at p0.05. Statistical analyses were
performed using JMP (Version 12, SAS Institute Inc., Cary, NC,
USA).
7. Ethical approval
This study was approved by the Yokosuka Kyousai Hospital
Ethics Committee, as well as by the School of Pharmacy, Nihon
University Ethics Committee. All procedures performed in studies
involving human participants were in accordance with the ethical
standards of the institutional and/or national research committee




During the 2-year research period, 100 patients were hospital-
ized in the Cardiovascular Medicine Department of Yokosuka
Kyousai Hospital for ablation of arrhythmias. Of these, 38 patients
did not have heart failure and 5 had missing data ; data of the re-
maining 57 patients were analyzed.
2. Patients’ background data at baseline
Baseline background data for all patients are shown in Table 1.
There were no significant differences between the groups on all
parameters.
3. Baseline clinical laboratory data
Baseline clinical laboratory data are shown in Table 2. AST and
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ALT were significantly higher in the Intervention group than in the
Usual care group (AST : 29.0 [23.041.0] IU/L vs. 26.0 [20.029.0]
IU/L, p=0.0335 ; ALT : 27.0 [23.034.0] IU/L vs. 21.0 [15.027.0]
IU/L, p = 0.0062). There were no significant differences between
the groups on all other parameters.
4. Main outcome measures
TTR was significantly higher in the Intervention group than in
the Usual care group (73.8% [61.493.4] vs. 59.8% [44.277.4], p =
0.0169). The sub-therapeutic range was significantly lower in the
Intervention group than in the Usual care group (3.8% [0.322.4]
vs. 22.2% [7.234.8], p = 0.0023). However, no significant differ-
ences between groups were observed for the supra-therapeutic
range. Major bleeding occurred in fewer patients in the Interven-
tion group (2/25 patients ; 8.0%) than in the Usual care group (4/32
patients ; 12.5%) ; however, there were no significant differences
between groups. Incidence of minor bleeding was almost identi-
cal in both groups (28%).
DISCUSSION
The most important finding of the present study was that inter-
vention by hospital pharmacists led to a significant improvement in
the anticoagulation control compared with the usual care. This
finding is attributable to the fact that hospital pharmacists carefully
instructed patients, placing attention on efficacy, side effects, and
interactions with foods. Such findings are consistent with results in
previously published studies (13-15). However, we previously re-
ported that TTR control of WF therapy was negatively affected in
NVAF patients with heart failure (7). There have been few reports
regarding TTR control of NVAF patients with heart failure. There-
fore, the findings obtained in the present study have novelty. If TTR
control among NVAF patients with heart failure improves through
intervention of hospital pharmacists, this could lead to a decreased
incidence of cerebral infarction or complications such as bleeding.
The absorption of drugs administered to patients with heart fail-
ure may be poor owing to certain factors such as decreased blood
flow or edema in the gastrointestinal tract. In general, in left heart
failure patients, drugs to be excreted in the urine are retained in the
blood by decreased urinary excretion due to decreased renal blood
flow rate ; hepatic metabolism is also delayed due to decreased
hepatic blood flow rate, and the blood drug concentration in-
creases. Alternatively, in right heart failure patients, blood drug
concentration remains constant because they maintain equilib-
rium with tissue compartment. In addition, we must consider that
renal and liver clearance is decreased when renal blood and hepatic
blood flows are decreased. Therefore, we believe that WF levels in
the blood may vary owing to hemodynamic fluctuations. Indeed,
our previous research revealed that heart failure was associated
with poor TTR control (7). Improving TTR control requires inter-
vention by hospital pharmacists rather than leaving TTR manage-
ment up to a sole physician.
In the present study, TTR improved approximately 14% ; TTR of
the Intervention and Usual care groups were approximately 74%
and 60%, respectively. Samsa et al. reported that TTR improved by
5% through patient self -management (16). The value obtained in
the present study is much higher than that of Samsa et al. ; thus, we
feel that intervention of hospital pharmacists is extremely useful in
TTR control. In addition, approximately 40% of patients in the Inter-
vention group vs. 21% in the Usual care group had TTR of approxi-
mately 80% or more, which indicates extremely good TTR con-
trol. In other words, pharmacotherapy collaboration of physicians
and hospital pharmacists may be one factor that contributes to the
success of anticoagulant therapy, since TTR control of the Interven-
tion group was approximately two-fold higher than that of the
Usual care group. On the other hand, when TTR is low, we cannot
expect therapeutic efficacy of WF, which increases the risk of
complications (5). A previous report showed that when TTR was
65%, the therapeutic effect of WF could not be achieved (5). In the
Table1 : Baseline participant background data
Characteristic Intervention group(n = 25)
Usual care group
(n = 32) p value
Male n, (%) 12 (48) 23(71.9) 0.0662 c)
Age (y) 70 [6476.5] 72[66.376.8] 0.5514 b)
Body weight (kg) 61.38.9 62.611.7 0.6623 a)
Body mass index (kg/m2) 24.42.8 23.53.2 0.2825 a)
Complications n, (%)
Hypertension 19 (76) 18(56.3) 0.1211 c)
Type 2 diabetes 2 (8) 10(31.3) 0.3385 d)
Stroke 5 (20) 4(12.5) 0.5828 d)
Transient ischemic attacks 0 (0) 1(3.1) 0.3725 d)
Dyslipidemia 12 (48) 9(28.1) 0.1227 c)
Smoking history n, (%) 8 (32) 17(53.1) 0.1551 c)
Average WF dose (mg) 3.1 [2.53.8] 2.8[2.24.3] 0.5571 b)
Bleeding after WF administration n, (%) 9 (36) 13(40.6) 0.7219 c)
Bleeding history n, (%) 1 (4) 4(12.5) 0.2603 d)
CHADS2 score (points) 3 [23] 2[23] 0.6079 b)
No. of measurements of PT-INR (times) 9 [710] 8.5[7.09.8] 0.4332 b)
CV-INR 0.250.09 0.240.08 0.5832 a)
Values are meanSD or median (interquartile range) where appropriate.
Abbreviation : Prothrombin time international normalized ratio : PT-INR, coefficient of variation-INR : CV-INR
a) t - test, b) MannWhitney U test, c)χ2 test, d) Fisher’s exact test
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Table2 : Baseline laboratory data
Characteristic Intervention group(n = 25)
Usual care group
(n = 32) p value
SBP (mmHg) 126 [104133.5] 121.5 [112141.5] 0.3979 b)
DBP (mmHg) 74.812.3 75.614.2 0.8250 a)
AST (IU/L) 29 [2341] 26 [2029] 0.0335 b)
ALT (IU/L) 27 [2334] 21 [1527] 0.0062 b)
BUN (mg/dL) 15 [1320] 16 [1420] 0.5948 b)
Scr (mg/dL) 0.81 [0.740.94] 0.82 [0.621.07] 0.8218 b)
eGFR (mL/min/1.73 m2) 62.014.4 70.021.4 0.3285 a)
T-Cho (mg/dL) 177.638.9 157.734.5 0.0687 a)
TG (mg/dL) 87 [57.5128] 87 [62.5126] 1.0000 b)
HDL-C (mg/dL) 54 [45.364.8] 47 [39.360] 0.2436 b)
LDL-C (mg/dL) 102.528.0 92.022.9 0.1428 a)
CRP (mg/dL) 0.18 [0.060.62] 0.27 [0.090.77] 0.4507 b)
TP (g/dL) 6.90.6 6.90.6 0.7150 a)
Alb (g/dL) 3.90.5 3.80.4 0.2049 b)
RBC (×106/μL) 4.40.5 4.20.7 0.1555 b)
Hb (g/dL) 13.81.4 13.22.1 0.1962 b)
Hct (%) 41.93.6 40.16.1 0.2013 b)
BNP (pg/mL) 184.2 [88.5287.4] 175.4 [77.9350.9] 0.8400 b)
Values are meanSD or median (interquartile range) where appropriate.
a) t - test, b) MannWhitney U test
Table3 : Anticoagulation control (TTR) in Intervention and Usual care groups.
Outcomes Intervention group(n = 25)
Usual care group
(n = 32) p value
Supra- therapeutic range (%) 13.9 [0.524.2] 4.4 [015.9] 0.2012
Within- therapeutic range (%) 73.8 [61.493.4] 59.8 [44.277.4] 0.0169
Sub- therapeutic range (%) 3.8 [0.322.4] 22.2 [7.234.8] 0.0023
Values are median (interquartile range) where appropriate. Supra- therapeutic range represents PT-INR 2.6 and sub-
therapeutic range represents PT-INR1.6. Within- therapeutic range represents 1.6PT-INR2.6.
The MannWhitney U test was used to compare the Intervention group with the Usual care group.
Abbreviation : Time in therapeutic range : TTR, Prothrombin time international normalized ratio : PT-INR
Table4 : Effect of Intervention versus Usual care groups on major bleeding and minor bleeding
Outcomes Intervention group(n = 25)
Usual care group
(n = 32) p value
Major bleeding
No. of patients with event n, (%) 2 (8) 4 (12.5) 0.8268 a)
Total of person-years of follow-up 51.5 47.6
No. of events per 100 person-years 3.9 8.4
Outcomes Intervention group(n = 25)
Usual care group
(n = 32) p value
Minor bleeding
No. of patients with event n, (%) 7 (28) 9 (28.1) 0.9323 b)
Total of person-years of follow-up 51.5 47.6
No. of events per 100 person-years 13.6 18.9
a) Fisher’s exact test, b) χ2 test
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current study, TTR in the Usual care group was approximately 60%.
We therefore suggest that WF may not have reached its full thera-
peutic potential. Although the reason for the low TTR in the Usual
care group is unknown, it is likely attributable to the following ex-
planation : the sub-therapeutic range was 22.9% in the Usual care
group and significantly exceeded 3.8% in the Intervention group. In
other words, poor adherence may be due to insufficient under-
standing regarding complex considerations, complications, medi-
cations, or interactions with food or supplements. Thus, in order to
properly maintain TTR, these instructions should be based on the
patient’s background (i.e., dietary habits) ; further, when patients
purchase medications at other medical institutions or pharmacies,
they should be given instruction regarding interactions with WF.
Although major bleeding after WF occurred in both groups
(13% of patients), this complication was not fatal due to appro-
priate treatment. Minor bleeding occurred in equal proportions
(less than a third) of patients in the two groups. Overall, there
were no significant differences between the two groups in major
and minor bleedings. However, while not significantly different,
the Intervention group had a higher value than the Usual care
group in the supra-therapeutic range, leading us to conclude that
more bleeding events occurred in the Intervention group than in
the Usual care group. Actuality, major bleeding occurrences were
higher in the Usual care group than in the Intervention group. This
was due to one patient who showed a high value in the supra-the-
rapeutic range (64.1%) in the Intervention group, which superfi-
cially inflated the value.
Collaborated anticoagulation care has been accepted as the
model of care in many advanced countries (17). Physicians set the
diagnoses and disease treatment goals and indicate the specific
management of anticoagulant therapy to pharmacists in the Kooteni
Medical Center located in the United States of Northern Idaho. In
other words, pharmacists administrate WF or heparin according to
the protocol established for each drug and instruct the necessary
clinical laboratory tests or create medical records, and conduct the
management of anticoagulation therapy (18). It is unknown whether
the same procedure will be adopted in Japan in the future. How-
ever, in recent years, pharmacists have been required to partici-
pate in multidisciplinary medical teams and to engage in proactive
pharmacotherapy. Pharmacists should attempt to improve patient
outcomes by assessing the management of pharmacotherapy,
taking advantage of pharmacists’ expertise regarding the antico-
agulation therapy of WF.
Several key strengths should be highlighted. First, a recent meta-
analysis suggested that a follow-up time of6 months would be
required to capture all dimensions of pharmacist -managed WF
therapy effects on clinical outcomes (13). Our study met that
criteria, demonstrating a significant effect on TTR and non-signi-
ficant effects on lesser complications. Second, our study overcame
the limitations of previous local studies (19-20) (i.e., short follow-up
period, lack of control group). Third, there have been few reports
focusing on NVAF patients with heart failure. Thus, we believe that
the patients in this study provided a realistic representation of pa-
tients receiving WF therapy in advanced countries.
This study had several limitations. First, the study followed a
single-center retrospective cohort design. Multi -center prospec-
tive cohort studies should be conducted based on the results of this
study. Second, the severity of heart failure in subjects was un-
known. Pharmacokinetics of WF may fluctuate because the amount
of circulating plasma can differ depending on the severity of heart
failure. However, since BNP in both groups did not significantly
differ, it is less likely that it affected the results of this study. Third,
the presence or absence of the onset of cerebral infarction was not
confirmed because the observation period was as short as 1 year in
the present study. We should set the incidence of thrombosis as the
primary outcome. However, thrombosis takes a long time to de-
velop. A large clinical trial is required to evaluate thrombosis as the
primary outcome. Thus, the present study evaluated TTR control
as the surrogate outcome. Fourth, a previous study showed that
other factors cause fluctuation of patient plasma prothrombin time,
such as being carriers of WF susceptibility genes (e.g., cyto-
chrome P450 2C9 and vitamin K epoxide reductase complex
subunit 1, intake of vitamin-K-containing foods, medication adher-
ence, or drug interactions (21). However, we were unable to investi-
gate these factors due to the retrospective nature of this study.
Therefore, there is a possibility that these factors influenced the
results of this study.
In conclusion, the present study revealed that TTR control among
NVAF patients with heart failure improved through intervention of
hospital pharmacists in addition to instruction by physicians. There-
fore, intervention of hospital pharmacists in anticoagulation therapy
can lead to the proper use of WF, which can be useful when physi-
cians prescribe WF. Further study is needed to clarify whether the
intervention of pharmacists prevent the incidence of thrombosis
based on the results of the present study.
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